Ann: Quarterly Update and Appendix 4C - quarterly, page-3

Yeah I also liked the rolling out of dosing...

PARA_OA_002 Phase 3 Clinical Trial
• On 6 July, Paradigm reported it had activated the first UK site in the global phase 3 clinical
trial. This first site is located at the University of Leeds under lead investigator Prof.
Hemant Pandit, with participant screening and enrolment commencing during Q3.
Paradigm aims to activate a total of seven sites across the UK for the phase 3 study.

• Regulatory approval from Health Canada for the phase 3 study was also reported in July.
Paradigm can also confirm it has since achieved ethics approval from the research ethics
board in Canada. The Company may now commence clinical trial site activation in Canada
where it plans to activate up to 10 sites. First participant enrolled into the PARA_OA_002
study will be reported once achieved.




Canada ethics done...will soon start at 10 separate sites...

This is good progress...more sites, more data...